Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial.

Ishii H, Oura T, Takeuchi M

Diabetes therapy : research, treatment and education of diabetes and related disorders16 Oct 2023Cited by 8 (Europe PMC)

PMID37843771PMCIDPMC10597937DOI10.1007/s13300-023-01485-3PepBankPUB-37843771

Read at source PubMedAsk about this study

Jump to 22 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study22

22 results from studies that gave the peptide. 22 results from people.

01HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes, tirzepatide 5 mg increased treatment satisfaction compared with dulaglutide.
In plain wordsIn Japanese patients with diabetes, treatment satisfaction was higher with tirzepatide 5 mg than dulaglutide.
Peptide
Tirzepatide
Outcome
IncreaseDTSQc overall satisfaction
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Whole body
Studied dose
5 mg once weekly · 52 weeksAs given in this study (human).
Measurements
DTSQc score
11.5 points
tirzepatide 5 mg
DTSQc score
8.9 points
dulaglutide
Source sentences
Summary
Mean overall DTSQc treatment satisfaction scores at week 52 were significantly higher with tirzepatide 5, 10, and 15 mg versus dulaglutide 0.75 mg (11.5, 12.1, and 12.3, respectively, vs 8.9; P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377101
02HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes, tirzepatide 10 mg increased treatment satisfaction compared with dulaglutide.
In plain wordsIn Japanese patients with diabetes, treatment satisfaction was higher with tirzepatide 10 mg than dulaglutide.
Peptide
Tirzepatide
Outcome
IncreaseDTSQc overall satisfaction
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Whole body
Studied dose
10 mg once weekly · 52 weeksAs given in this study (human).
Measurements
DTSQc score
12.1 points
tirzepatide 10 mg
DTSQc score
8.9 points
dulaglutide
Source sentences
Summary
Mean overall DTSQc treatment satisfaction scores at week 52 were significantly higher with tirzepatide 5, 10, and 15 mg versus dulaglutide 0.75 mg (11.5, 12.1, and 12.3, respectively, vs 8.9; P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377102
03HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes, tirzepatide 15 mg increased treatment satisfaction compared with dulaglutide.
In plain wordsIn Japanese patients with diabetes, treatment satisfaction was higher with tirzepatide 15 mg than dulaglutide.
Peptide
Tirzepatide
Outcome
IncreaseDTSQc overall satisfaction
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Whole body
Studied dose
15 mg once weekly · 52 weeksAs given in this study (human).
Measurements
DTSQc score
12.3 points
tirzepatide 15 mg
DTSQc score
8.9 points
dulaglutide
Source sentences
Summary
Mean overall DTSQc treatment satisfaction scores at week 52 were significantly higher with tirzepatide 5, 10, and 15 mg versus dulaglutide 0.75 mg (11.5, 12.1, and 12.3, respectively, vs 8.9; P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377103
04HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes, treatment satisfaction was lower with dulaglutide than tirzepatide 5 mg.
In plain wordsIn Japanese patients with diabetes, treatment satisfaction was lower with dulaglutide than tirzepatide 5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDTSQc overall satisfaction
Study
n: not reported in source
Comparator
Tirzepatide 5 mg
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Whole body
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Measurements
DTSQc score
8.9 points
dulaglutide 0.75 mg
DTSQc score
11.5 points
tirzepatide 5 mg
Source sentences
Summary
Mean overall DTSQc treatment satisfaction scores at week 52 were significantly higher with tirzepatide 5, 10, and 15 mg versus dulaglutide 0.75 mg (11.5, 12.1, and 12.3, respectively, vs 8.9; P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377104
05HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes, treatment satisfaction was lower with dulaglutide than tirzepatide 10 mg.
In plain wordsIn Japanese patients with diabetes, treatment satisfaction was lower with dulaglutide than tirzepatide 10 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDTSQc overall satisfaction
Study
n: not reported in source
Comparator
Tirzepatide 10 mg
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Whole body
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Measurements
DTSQc score
8.9 points
dulaglutide 0.75 mg
DTSQc score
12.1 points
tirzepatide 10 mg
Source sentences
Summary
Mean overall DTSQc treatment satisfaction scores at week 52 were significantly higher with tirzepatide 5, 10, and 15 mg versus dulaglutide 0.75 mg (11.5, 12.1, and 12.3, respectively, vs 8.9; P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377105
06HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes, treatment satisfaction was lower with dulaglutide than tirzepatide 15 mg.
In plain wordsIn Japanese patients with diabetes, treatment satisfaction was lower with dulaglutide than tirzepatide 15 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDTSQc overall satisfaction
Study
n: not reported in source
Comparator
Tirzepatide 15 mg
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Whole body
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Measurements
DTSQc score
8.9 points
dulaglutide 0.75 mg
DTSQc score
12.3 points
tirzepatide 15 mg
Source sentences
Summary
Mean overall DTSQc treatment satisfaction scores at week 52 were significantly higher with tirzepatide 5, 10, and 15 mg versus dulaglutide 0.75 mg (11.5, 12.1, and 12.3, respectively, vs 8.9; P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377106
07HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes, perceived hyperglycemia frequency scores were lower with tirzepatide 5 mg than dulaglutide.
In plain wordsIn Japanese patients with diabetes, perceived high blood sugar scores were lower with tirzepatide 5 mg than dulaglutide.
Peptide
Tirzepatide
Outcome
DecreasePerceived unacceptable hyperglycemia
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mg once weekly · 52 weeksAs given in this study (human).
Measurements
DTSQc hyperglycemia score
−1.7 points
tirzepatide 5 mg
DTSQc hyperglycemia score
−0.6 points
dulaglutide
Source sentences
Summary
The DTSQc perceived frequency scores for unacceptable hyperglycemia were significantly lower with tirzepatide 5, 10, and 15 mg versus dulaglutide 0.75 mg (- 1.7, - 1.8, and - 2.3, respectively, vs - 0.6; P < 0.001),
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377107
08HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes, perceived hyperglycemia frequency scores were lower with tirzepatide 10 mg than dulaglutide.
In plain wordsIn Japanese patients with diabetes, perceived high blood sugar scores were lower with tirzepatide 10 mg than dulaglutide.
Peptide
Tirzepatide
Outcome
DecreasePerceived unacceptable hyperglycemia
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg once weekly · 52 weeksAs given in this study (human).
Measurements
DTSQc hyperglycemia score
−1.8 points
tirzepatide 10 mg
DTSQc hyperglycemia score
−0.6 points
dulaglutide
Source sentences
Summary
The DTSQc perceived frequency scores for unacceptable hyperglycemia were significantly lower with tirzepatide 5, 10, and 15 mg versus dulaglutide 0.75 mg (- 1.7, - 1.8, and - 2.3, respectively, vs - 0.6; P < 0.001),
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377108
09HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes, perceived hyperglycemia frequency scores were lower with tirzepatide 15 mg than dulaglutide.
In plain wordsIn Japanese patients with diabetes, perceived high blood sugar scores were lower with tirzepatide 15 mg than dulaglutide.
Peptide
Tirzepatide
Outcome
DecreasePerceived unacceptable hyperglycemia
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mg once weekly · 52 weeksAs given in this study (human).
Measurements
DTSQc hyperglycemia score
−2.3 points
tirzepatide 15 mg
DTSQc hyperglycemia score
−0.6 points
dulaglutide
Source sentences
Summary
The DTSQc perceived frequency scores for unacceptable hyperglycemia were significantly lower with tirzepatide 5, 10, and 15 mg versus dulaglutide 0.75 mg (- 1.7, - 1.8, and - 2.3, respectively, vs - 0.6; P < 0.001),
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377109
10HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes, perceived hyperglycemia scores were higher with dulaglutide than tirzepatide 5 mg.
In plain wordsIn Japanese patients with diabetes, perceived high blood sugar scores were higher with dulaglutide than tirzepatide 5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreasePerceived unacceptable hyperglycemia
Study
n: not reported in source
Comparator
Tirzepatide 5 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Measurements
DTSQc hyperglycemia score
−0.6 points
dulaglutide 0.75 mg
DTSQc hyperglycemia score
−1.7 points
tirzepatide 5 mg
Source sentences
Summary
The DTSQc perceived frequency scores for unacceptable hyperglycemia were significantly lower with tirzepatide 5, 10, and 15 mg versus dulaglutide 0.75 mg (- 1.7, - 1.8, and - 2.3, respectively, vs - 0.6; P < 0.001),
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377110
11HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes, perceived hyperglycemia scores were higher with dulaglutide than tirzepatide 10 mg.
In plain wordsIn Japanese patients with diabetes, perceived high blood sugar scores were higher with dulaglutide than tirzepatide 10 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreasePerceived unacceptable hyperglycemia
Study
n: not reported in source
Comparator
Tirzepatide 10 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Measurements
DTSQc hyperglycemia score
−0.6 points
dulaglutide 0.75 mg
DTSQc hyperglycemia score
−1.8 points
tirzepatide 10 mg
Source sentences
Summary
The DTSQc perceived frequency scores for unacceptable hyperglycemia were significantly lower with tirzepatide 5, 10, and 15 mg versus dulaglutide 0.75 mg (- 1.7, - 1.8, and - 2.3, respectively, vs - 0.6; P < 0.001),
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377111
12HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes, perceived hyperglycemia scores were higher with dulaglutide than tirzepatide 15 mg.
In plain wordsIn Japanese patients with diabetes, perceived high blood sugar scores were higher with dulaglutide than tirzepatide 15 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreasePerceived unacceptable hyperglycemia
Study
n: not reported in source
Comparator
Tirzepatide 15 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Measurements
DTSQc hyperglycemia score
−0.6 points
dulaglutide 0.75 mg
DTSQc hyperglycemia score
−2.3 points
tirzepatide 15 mg
Source sentences
Summary
The DTSQc perceived frequency scores for unacceptable hyperglycemia were significantly lower with tirzepatide 5, 10, and 15 mg versus dulaglutide 0.75 mg (- 1.7, - 1.8, and - 2.3, respectively, vs - 0.6; P < 0.001),
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377112
13HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes, perceived hypoglycemia scores were similar across tirzepatide and dulaglutide arms.
In plain wordsIn Japanese patients with diabetes, perceived low blood sugar scores were similar with tirzepatide and dulaglutide.
Peptide
Tirzepatide
Outcome
No significant changePerceived unacceptable hypoglycemia
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Measurements
DTSQc hypoglycemia score
−1.1 to −0.8 points
all treatment arms
Source sentences
Summary
while scores for unacceptable hypoglycemia were similar across all treatment arms, ranging from - 0.8 to - 1.1.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377113
14HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes, perceived hypoglycemia scores were similar across dulaglutide and tirzepatide arms.
In plain wordsIn Japanese patients with diabetes, perceived low blood sugar scores were similar with dulaglutide and tirzepatide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePerceived unacceptable hypoglycemia
Study
n: not reported in source
Comparator
Tirzepatide
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Measurements
DTSQc hypoglycemia score
−1.1 to −0.8 points
all treatment arms
Source sentences
Summary
while scores for unacceptable hypoglycemia were similar across all treatment arms, ranging from - 0.8 to - 1.1.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377114
15HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes below 65 years, tirzepatide increased satisfaction compared with dulaglutide.
In plain wordsIn Japanese patients with diabetes below 65 years, satisfaction was higher with tirzepatide than dulaglutide.
Peptide
Tirzepatide
Outcome
IncreaseSatisfaction in patients below 65 years
Study
n: not reported in source
Comparator
Dulaglutide
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Subgroup analyses showed increased treatment satisfaction with tirzepatide compared with dulaglutide in the 2 subgroups (P 2 subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377115
16HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes below 65 years, satisfaction was lower with dulaglutide than tirzepatide.
In plain wordsIn Japanese patients with diabetes below 65 years, satisfaction was lower with dulaglutide than tirzepatide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseSatisfaction in patients below 65 years
Study
n: not reported in source
Comparator
Tirzepatide
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Subgroup analyses showed increased treatment satisfaction with tirzepatide compared with dulaglutide in the 2 subgroups (P 2 subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377116
17HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes and BMI ≥25 kg/m², tirzepatide increased satisfaction compared with dulaglutide.
In plain wordsIn Japanese patients with diabetes and BMI ≥25, satisfaction was higher with tirzepatide than dulaglutide.
Peptide
Tirzepatide
Outcome
IncreaseSatisfaction at BMI at least 25
Study
n: not reported in source
Comparator
Dulaglutide
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Subgroup analyses showed increased treatment satisfaction with tirzepatide compared with dulaglutide in the 2 subgroups (P 2 subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377117
18HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes and BMI ≥25 kg/m², satisfaction was lower with dulaglutide than tirzepatide.
In plain wordsIn Japanese patients with diabetes and BMI ≥25, satisfaction was lower with dulaglutide than tirzepatide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseSatisfaction at BMI at least 25
Study
n: not reported in source
Comparator
Tirzepatide
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Subgroup analyses showed increased treatment satisfaction with tirzepatide compared with dulaglutide in the 2 subgroups (P 2 subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377118
19HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes aged ≥65 years, satisfaction was similar with tirzepatide and dulaglutide.
In plain wordsIn Japanese patients with diabetes aged ≥65 years, satisfaction was similar with tirzepatide and dulaglutide.
Peptide
Tirzepatide
Outcome
No significant changeSatisfaction in patients at least 65 years
Study
n: not reported in source
Comparator
Dulaglutide
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Subgroup analyses showed increased treatment satisfaction with tirzepatide compared with dulaglutide in the 2 subgroups (P 2 subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377119
20HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes aged ≥65 years, satisfaction was similar with dulaglutide and tirzepatide.
In plain wordsIn Japanese patients with diabetes aged ≥65 years, satisfaction was similar with dulaglutide and tirzepatide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeSatisfaction in patients at least 65 years
Study
n: not reported in source
Comparator
Tirzepatide
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Subgroup analyses showed increased treatment satisfaction with tirzepatide compared with dulaglutide in the 2 subgroups (P 2 subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377120
21HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes and BMI <25 kg/m², satisfaction was similar with tirzepatide and dulaglutide.
In plain wordsIn Japanese patients with diabetes and BMI <25, satisfaction was similar with tirzepatide and dulaglutide.
Peptide
Tirzepatide
Outcome
No significant changeSatisfaction at BMI below 25
Study
n: not reported in source
Comparator
Dulaglutide
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Subgroup analyses showed increased treatment satisfaction with tirzepatide compared with dulaglutide in the 2 subgroups (P 2 subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377121
22HumanNon-randomized trialEfficacy outcome
In Japanese patients with diabetes and BMI <25 kg/m², satisfaction was similar with dulaglutide and tirzepatide.
In plain wordsIn Japanese patients with diabetes and BMI <25, satisfaction was similar with dulaglutide and tirzepatide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeSatisfaction at BMI below 25
Study
n: not reported in source
Comparator
Tirzepatide
Analysis
Exploratory
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Subgroup analyses showed increased treatment satisfaction with tirzepatide compared with dulaglutide in the 2 subgroups (P 2 subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment with once-weekly tirzepatide (5, 10, and 15 mg) compared with dulaglutide 0.75 mg.
Summary · context
This exploratory analysis of the phase 3 SURPASS J-mono trial assessed treatment satisfaction using the Japanese translation of the Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change versions (DTSQc).
Report a problemFND-3784377122

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03861052

A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

Eli Lilly and Companyn = 6367 May 2019 to 31 Mar 2021

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 14 Apr 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC